A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties

被引：0
|
作者：
Wuellner, Ulrich [1 ]
Buller, Fabian [1 ]
Klupsch, Kristina [1 ]
Brack, Simon [1 ]
Zbinden, Irene [1 ]
Santimaria, Roger [1 ]
Attinger-Toller, Isabella [1 ]
Koenig-Friedrich, Susann [1 ]
Bertschinger, Julian [1 ]
Grabulovski, Dragan [1 ]
机构：
[1] Covagen AG, Zurich, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
656
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1
    Li, Ji
    Hristopoulos, Maria
    Clark, Robyn
    Johnston, Jennifer
    Slaga, Dion
    Wang, Bu-Er
    Cubas, Rafael
    Totpal, Klara
    Junttila, Melissa R.
    Junttila, Teemu T.
    CANCER RESEARCH, 2016, 76
  • [32] MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth
    Zhang, Bo
    Stephanie Nguyen
    Huhalov, Alexandra
    Nielsen, Ulrik B.
    Niyikiza, Clet
    McDonagh, Charlotte F.
    Kudia, Arthur J.
    Onsum, Matthew
    CANCER RESEARCH, 2012, 72
  • [33] Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Gallenne, Tristan
    Maussang-Detaille, David
    Kramer, Arjen
    Nieuwenhuizen, Nellie
    Clements, Carina
    van Zoest, Katinka
    Nijhuis, Roy
    Visser, Therese
    Den Blanken-Smit, Renate
    Bartelink, Willem
    Zondag-van der Zande, Vanessa
    Kaldenberg, Linda
    van Loo, Pieter-Fokko
    Roovers, Rob
    Doornbos, Robert
    Price, Leo
    Braam, Stefan
    van Driel, Setareh
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    CANCER RESEARCH, 2015, 75
  • [34] D3L-001, a novel bispecific antibody targeting HER2 and CD47, demonstrates potent preclinical efficacy in solid tumors
    Rui, Haopeng
    Yang, Xiaofeng
    Chen, Jiahao
    Wang, Jia
    Zheng, Zhiqiang
    Chen, Zhiqiang
    Lu, Jingtao
    Wu, Peggy
    Chen, Janet
    Wang, Allison
    Chen, George
    CANCER RESEARCH, 2023, 83 (07)
  • [35] MG1122, a whole IgG-like bispecific antibody targeting mesothelin and CD3, induces T cell-mediated killing of MSLN-expressing tumor cells
    Lee, Yun-Jung
    Lim, Okjae
    Kim, Munkyung
    Lee, Jeewon
    Kim, Kisu
    Jung, Junhong
    Lee, Sua
    Kim, Sung Keun
    Kwon, Haenaem
    Lim, Yangmi
    Park, Yong Yea
    Won, Jonghwa
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Nonclinical Safety Profile of Anti-HER2/CD3 T-Cell-Dependent Bispecific (TDB) Antibodies
    Staflin, K.
    Schutt, L.
    Junttila, T.
    De Zafra, C.
    Katavolos, P.
    Dybdal, N.
    Totpal, K.
    Li, J.
    Hristopoulos, M.
    Clark, R.
    Ybarra, R.
    Junttila, M.
    Slaga, D.
    Johnston, J.
    Dennis, M.
    Mathieu, M.
    Chen, X.
    Ellerman, D.
    Zhong, F.
    Clark, V.
    Shelton, A.
    Prell, R.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2019, 38 (01) : 43 - 43
  • [37] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
    Wu, Danqing
    Gong, Shiyong
    Wu, Xuan
    Naren, Gaowa
    Dong, Liqin
    Lensky, Stephan
    Wu, Chengbin
    CANCER RESEARCH, 2024, 84 (07)
  • [38] Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Nijhuis, Roy
    den Blanken-Smit, Renate
    Visser, Therese
    Bartelink, Willem
    Kramer, Arjen
    Zondag-van der Zande, Vanessa
    Clements, Carina
    Kaldenberg, Linda
    Nieuwenhuizen, Nellie
    van Loo, Pieter Fokko
    Roovers, Rob
    Gallenne, Tristan
    Price, Leo
    Shamsili, Setareh Van Driel
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Preclinical development of a bispecific antibody-trap selectively targeting CD47 and HER2 for the treatment of breast as well as gastric cancer
    Tian, Wenzhi
    Li, Song
    Chen, Dianze
    Liu, Dandan
    Guo, Huiqin
    Yang, Chunmei
    Zhang, Li
    Zhang, Wei
    Tu, Xiaoping
    Peng, Liang
    Zhao, Gui
    Zhang, Ruliang
    Zhang, Fan
    CANCER RESEARCH, 2022, 82 (12)
  • [40] ENGINEERING HIGH-AFFINITY HUMANIZED ANTI-P185(HER2)/ANTI-CD3 BISPECIFIC F(AB')(2) FOR EFFICIENT LYSIS OF P185(HER2) OVEREXPRESSING TUMOR-CELLS
    ZHU, ZP
    LEWIS, GD
    CARTER, P
    INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (03) : 319 - 324
12345